Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation

References

• EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Long J, Zheng JS, Sun B, et al. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. Hepatol Int. 2016;10(1):175–184.
   PubMed Web of Science ®Google Scholar
• Cao F, Shen L, Qi H, et al. Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion. Aging. 2019;11(21):9544–9555.
   PubMedGoogle Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853.
   PubMed Web of Science ®Google Scholar
• Chan SL, Chong CC, Chan AW, et al. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J Gastroenterol. 2016;22(32):7289–7300.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Chen ZH, Zhang XP, Lu YG, et al. Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study. Hepatol Int. 2020;14(5):754–764.
   PubMed Web of Science ®Google Scholar
• Liu PH, Huo TI, Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Semin Liver Dis. 2018;38(3):242–251.
   PubMed Web of Science ®Google Scholar
• Bouvry C, Palard X, Edeline J, et al. Transarterial radioembolization (TARE) agents beyond 90Y-Microspheres . Biomed Res Int. 2018;2018:1435302.
   PubMed Web of Science ®Google Scholar
• Crane CH, O’Reilly EM. Ablative radiotherapy doses for locally advanced: pancreatic cancer (LAPC). Cancer J. 2017;23(6):350–354.
   PubMed Web of Science ®Google Scholar
• Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38(36):4317–4345.
   PubMed Web of Science ®Google Scholar
• Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.
   PubMed Web of Science ®Google Scholar
• Yamada S, Utsunomiya T, Morine Y, et al. Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Ann Surg Oncol. 2014;21(S3):436–442.
   Web of Science ®Google Scholar
• Su T, Liao J, Dai Z, et al. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Oncogene. 2018;37(26):3514–3527.
   PubMed Web of Science ®Google Scholar
• Ierardi AM, Biondetti P, Coppola A, et al. Percutaneous microwave thermosphere ablation of pancreatic tumours. Gland Surg. 2018;7(2):59–66.
   PubMed Web of Science ®Google Scholar
• Hlavsa J, Procházka V, Andrasina T, et al. Radiofrequency ablation in pancreatic cancer. Rozhl Chir. 2019;98(11):441–449.
   PubMedGoogle Scholar
• Zheng JS, Long J, Sun B, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: extending the indication for ablation? Clin Radiol. 2014;69(6):e253–e263.
   PubMed Web of Science ®Google Scholar
• Giorgio A, Calisti G, Montesarchio L, et al. Hepatocellular carcinoma invading portal venous system in cirrhosis: long-term results of percutaneous radiofrequency ablation of both the nodule and portal vein tumor thrombus. A case control study. Anticancer Res. 2014;34:6785–6790.
   PubMed Web of Science ®Google Scholar
• Ding X, Sun W, Chen J, et al. Percutaneous radiofrequency ablation combined with transarterial chemoembolization plus sorafenib for large hepatocellular carcinoma invading the portal venous system: a prospective randomized study. Front Oncol. 2020;10:578633.
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Pan T, et al. Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. Int J Hyperthermia. 2019;36(1):1003–1011.
   PubMed Web of Science ®Google Scholar
• Mu L, Sun L, Pan T, et al. Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results. Int J Hyperthermia. 2018;34(1):59–67.
   PubMed Web of Science ®Google Scholar
• Golfieri R, Bargellini I, Spreafico C, et al. Patients with barcelona clinic liver cancer stages B and C hepatocellular carcinoma: time for a Subclassification. Liver Cancer. 2019;8(2):78–91.
   PubMed Web of Science ®Google Scholar
• Schwarz RE, Abou-Alfa GK, Geschwind JF, et al. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010;12(5):313–320.
   PubMed Web of Science ®Google Scholar
• Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol. 2015;7(11):1553–1561.
   PubMed Web of Science ®Google Scholar
• Huang M, Lin Q, Wang H, et al. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study. Eur Radiol. 2016;26(10):3428–3436.
   PubMed Web of Science ®Google Scholar
• Kim JH, Shim JH, Yoon HK, et al. Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein. Liver Int. 2018;38(9):1646–1654.
   PubMed Web of Science ®Google Scholar
• Vitale A, Lai Q, Farinati F, et al. Utility of tumor burden score to stratify prognosis of patients with hepatocellular cancer: results of 4759 cases from ITA.LI.CA study group. J Gastrointest Surg. 2018;22(5):859–871.
   PubMed Web of Science ®Google Scholar
• Peng Z, Chen S, Wei M, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;287(2):705–714.
   PubMed Web of Science ®Google Scholar
• Oguro S, Yoshimoto J, Imamura H, et al. Clinical significance of macroscopic no-margin hepatectomy for hepatocellular carcinoma. HPB (Oxford). 2018;20(9):872–880.
   PubMed Web of Science ®Google Scholar
• Chung SR, Kim JH, Yoon HK, et al. Combined Cisplatin-Based chemoembolization and radiation therapy for hepatocellular carcinoma invading the main portal vein. J Vasc Interv Radiol. 2015;26(8):1130–1138.
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
   PubMed Web of Science ®Google Scholar
• Austin PC, Jembere N, Chiu M. Propensity score matching and complex surveys. Stat Methods Med Res. 2018;27(4):1240–1257.
   PubMed Web of Science ®Google Scholar
• Hu Y, Qin T, Li S, et al. Efficacy and safety of SBRT combined with camrelizumab and apatinib in HCC patients with PVTT: Study protocol of a randomized controlled trial. Front Oncol. 2020;10:1589.
   PubMed Web of Science ®Google Scholar
• Wei X, Jiang Y, Zhang X, et al. Neoadjuvant Three-Dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, Open-Label, multicenter controlled study. J Clin Oncol. 2019;37(24):2141–2151.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase IB study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970.
   PubMed Web of Science ®Google Scholar
• Lee JM, Jang BK, Lee YJ, et al. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol. 2016;22(1):160–167.
   PubMed Web of Science ®Google Scholar
• Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82(3):469–478.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Yuan J, Yin X, Tang B, et al. Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Biomed Res Int. 2019;2019:1–6.
   Web of Science ®Google Scholar
• Pracht M, Edeline J, Lenoir L, et al. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results. Int J Hepatol. 2013;2013:827649.
   PubMedGoogle Scholar
• Jia Z, Jiang G, Tian F, et al. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol. 2016;22(5):353–359.
   PubMed Web of Science ®Google Scholar
• Kaneko S, Tsuchiya K, Yasui Y, et al. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatol Res. 2020;50(12):1375–1385.
   PubMed Web of Science ®Google Scholar
• Ibrahim C, Parra N, Macedo FI, et al. Is hepatic resection better than transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis? J Gastrointest Oncol. 2019;10(6):1064–1072.
   PubMed Web of Science ®Google Scholar
• Li MX, Zhao H, Bi XY, et al. Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma. Tumour Biol. 2016;37(7):9301–9310.
   PubMedGoogle Scholar
• Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei integrated scoring system. J Hepatol. 2010;53(1):108–117.
   PubMed Web of Science ®Google Scholar
• Tan L, Chen S, Wei G, et al. Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner. Cancer Lett. 2019;460:29–40.
   PubMed Web of Science ®Google Scholar